Quantification of the carbapenem antibiotic ertapenem in human plasma by a validated liquid chromatography-mass spectrometry method

Clinica Chimica Acta

Volumn 364, Issue 1-2, 2006, Pages 239-245

  Koal, Therese ^a   Deters, Michael ^a   Resch, Klaus ^a   Kaever, Volkhard ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Antibiotic; Carbapenem; Ertapenem; LC MS

Indexed keywords

CARBAPENEM; CEFTAZIDIME; ERTAPENEM;

ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG ISOLATION; DRUG MONITORING; DRUG STABILITY; HUMAN; ION MONITORING; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NORMAL HUMAN; PRECIPITATION; PRIORITY JOURNAL;

BETA-LACTAMS; CALIBRATION; CARBAPENEMS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG STABILITY; HUMANS; KIDNEY FAILURE, CHRONIC; MASS SPECTROMETRY; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS;

EID: 31044450987     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cccn.2005.07.004     Document Type: Article

References (34)

1. G. Ortiz-Ruiz, J. Caballero-Lopez, I.R. Friedland, G.L. Woods, and A. Carides A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults Clin Infect Dis 34 2002 1076 1083
2. G. Bonfiglio, G. Russo, and G. Nicoletti Recent development in carbapenems Expert Opin Investig Drugs 11 2002 529 544
3. D.M. Livermore, M.W. Carter, S. Bagel, B. Wiedemann, F. Baquero, and E. Loza In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia Antimicrob Agents Chemother 45 2001 1860 1867
4. P.C. Fuchs, A.L. Barry, and S.D. Brown In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 North American medical centers Antimicrob Agents Chemother 45 2001 1915 1918
5. M.L. Hammond Ertapenem: a group 1 carbapenem with distinct antibacterial and pharmacological properties J Antimicrob Chemother 53 2004 ii7 ii9
6. H.M. Wexler In vitro activity of ertapenem: review of recent studies J Antimicrob Chemother 53 2004 ii11 ii21
7. M. Curran, D. Simpson, and C. Perry Ertapenem: a review of its use in the management of bacterial infections Drugs 63 2003 1855 1878
8. G.G. Zhanel, C. Johanson, J.M. Embil, A. Noreddin, A. Gin, and L. Vercaigne Ertapenem: review of a new carbapenem Expert Rev Anti Infect Ther 3 2005 23 39
9. D.E. Nix, A.K. Majumdar, and M.J. DiNubile Pharmacokinetics and pharmacodynamics of ertapenem: an overview for clinicians J Antimicrob Chemother 53 Suppl. S2 2004 ii23 ii28
10. n of degradated of a novel carbapenem antibiotic in an aqueous matrix J Pharm Biomed Anal 29 2002 173 181
11. M.W.R. Pletz, M. Rau, J. Bulitta, A. De Roux, O. Burkhardt, and G. Kruse Ertapenem pharmacokinetics and impact on intestinal microflora, in comparison to those of ceftriaxone, after multiple dosing in male and female volunteers Antimicrob Agents Chemother 48 2004 3765 3772
12. D.G. Musson, K.L. Birk, C.J. Kitchen, J. Zhang, J.Y.K. Hsieh, and W. Fang Assay methodology for the quantitation of unbound ertapenem, a new carbapenem antibiotic, in human plasma J Chromatogr B 783 2003 1 9
13. D.G. Musson, K.L. Birk, A.M. Cairns, A.K. Majumdar, and J.D. Rogers High-performance liquid chromatographic methods for the determination of a new carbapenem antibiotic, L-749,345 in human plasma and urine J Chromatogr B 720 1998 99 106
14. M. Ehrlich, F.D. Dascher, and K. Kummerer Rapid antibiotic drug monitoring: meropenem and ceftazidime determination in serum and bronchial secretions by high-performance liquid chromatography-integrated sample preparation J Chromatogr B 751 2001 357 363
15. D.G. Musson, A.K. Majumdar, K.L. Birk, S. Holland, P. Wickersham, and S.X. Li Pharmacokinetics of intramuscularly administered ertapenem Antimicrob Agents Chemother 47 2003 1732 1735
16. C. Robatel, T. Buclin, P. Eckert, M.D. Schaller, J. Biollaz, and L.A. Decosterd Determination of meropenem in plasma and filtrate-dialysate from patients under continuous veno-venous haemodiafiltration by SPE-LC J Pharm Biomed Anal 29 2002 17 33
17. J. Zhang, D.G. Musson, K.L. Birk, A.M. Cairns, A.L. Fisher, and W. Neway Direct-injection HPLC assay for the determination of a new carbapenem antibiotic in human plasma and urine J Pharm Biomed Anal 27 2002 755 770
18. T. Laethem, I. De Lepeleire, J. McCrea, J. Zhang, A. Majumdar, and D. Musson Tissue penetration by ertapenem, a parenteral carbapenem administered once daily, in suction-induced skin blister fluid in healthy young volunteers Antimicrob Agents Chemother 47 2003 1439 1442
19. C.J. Kitchen, D.G. Musson, and A.L. Fisher Column-switching technique for the sensitive determination of ertapenem in human cerebrospinal fluid using liquid chromatography and ultraviolet absorbance detection J Chromatogr B 799 2004 9 14
20. A.K. Majumdar, D.G. Musson, K.L. Birk, C.J. Kitchen, S. Holland, and J. McCrea Pharmacokinetics of ertapenem in healthy young volunteers Antimicrob Agents Chemother 46 2002 3506 3511
21. I. Tegeder, A. Schmidtko, L. Brautigam, A. Kirschbaum, G. Geisslinger, and J. Lötsch Tissue distribution of imipenem in critically ill patients Clin Pharmacol Ther 71 2002 325 333
22. C.J. Gill, J.J. Jackson, L.S. Gerckens, B.A. Pelak, R.K. Thomson, and J.G. Sundelof In vivo activity and pharmacokinetic evaluation of a novel long-acting carbapenem antibiotic, MK-826 (L-749,345) Antimicrob Agents Chemother 42 1998 1996 2001
23. T. Foitzik, H.G. Hotz, M. Kinzig, F. Sorgel, and H.J. Buhr Influence of changes in pancreatic tissue morphology and capillary blood flow on antibiotic tissue concentrations in the pancreas during the progression of acute pancreatitis Gut 40 1997 526 530
24. M. Büchler, P. Malfertheiner, H. Frieß, R. Isenmann, E. Vanek, and H. Grimm Human pancreatic tissue concentration of bactericidal antibiotics Gastroenterology 103 1992 1902 1908
25. M. Erttmann, R. Krausse, and U. Ullmann Pharmacokinetics of imipenem in patients undergoing major colon surgery Infection 18 1990 367 371
26. L. Kager, B. Brismar, A.S. Malmborgs, and C.E. Nord Imipenem concentrations in colorectal surgery and impact on the colonic microflora Antimicrob Agents Chemother 33 1989 204 208
27. F. Tomaselli, A. Maier, V. Matzi, F.M. Smolle-Juttner, and P. Dittrich Penetration of meropenem into pneumonic human lung tissue as measured by in vivo microdialysis Antimicrob Agents Chemother 48 2004 2228 2232
28. T. Bidgood, and M.G. Papich Plasma pharmacokinetics and tissue fluid concentrations of meropenem after intravenous and subcutaneous administration in dogs Am J Vet Res 63 2002 1622 1628
29. U. Saglamkaya, M.R. Mas, M. Yasar, I. Simek, N.N. Mas, and F. Kocabalkan Penetration of meropenem and cefepim into pancreatic tissue during the course of experimental acute pancreatitis Pancreas 24 2002 264 268
30. R.E. Condon, A.P. Walker, C.B. Hanna, R.N. Greenberg, A. Broom, and D. Pitkin Penetration of meropenem in plasma and abdominal tissue from patients undergoing intraabdominal surgery Clin Infect Dis 24 1997 S181 S183
31. S. Gall, D.L. Hemsell, J.A. McGregor, M.G. Martens, D. Pitkin, and S. Allen Tissue penetration of meropenem in patients undergoing gynecologic surgery Clin Infect Dis 24 1997 S178 S180
32. M. Hutchison, K.L. Faulkner, P.J. Turner, S.J. Haworth, W. Sheikh, and H. Nadler A compilation of meropenem tissue distribution data J Antimicrob Chemother 36 Suppl. A 1995 S43 S46
33. Guidance for Industry, Bioanalytical Method Validation, U.S. Department of Health and Human Services, Food and Drug administration, www.fda.gov/cder/ Guidance/4252fnl.pdf.
34. P.J. Taylor Matrix effects: the Achilles heel of quantitative high-performance liquid chromatography-electrospray-tandem mass spectrometry Clin Biochem 38 2005 328 334